 Home > Active Ingredient News > Drugs Articles > Sichuan pharmaceutical companies will win TOP1 anti-dementia drugs, and the retail market is soaring every year

Sichuan pharmaceutical companies will win TOP1 anti-dementia drugs, and the retail market is soaring every year

 Last Update: 2021-08-15
 Source: Internet
 Author: User

Tags

source resveratrol

id product source

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Sichuan Meidakang Pharmaceutical's application for the 4 types of generic listing of Memantine Hydrochloride Tablets has entered the approval status

Figure 1: Product information under review

Memantine is an excitatory amino acid receptor antagonist used to treat moderate to severe Alzheimer's dementia

According to data from Meinenet, Memantine defeated Donepezil and became the TOP1 anti-dementia drug in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) in 2020

Figure 2: The sales of Memantine in the retail market (unit: ten thousand yuan)

In the physical pharmacies of Chinese cities, the sales of Memantine are achieving rapid growth.

Data source: CDE official website, Minet database

Statistics are as of August 4th, please correct me if there are any errors or omissions

Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 cities and above cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
.
The above sales are calculated based on the average retail price of the product at the terminal
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.